Genetically Elevated C-Reactive Protein and Ischemic Vascular Disease
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated levels of C-reactive protein (CRP) are associated with increased risks of ischemic heart disease and ischemic cerebrovascular disease. We tested whether this is a causal association. METHODS: We studied 10,276 persons from a general population cohort, including 1786 in whom ischemic heart disease developed and 741 in whom ischemic cerebrovascular disease developed. We examined another 31,992 persons from a cross-sectional general population study, of whom 2521 had ischemic heart disease and 1483 had ischemic cerebrovascular disease. Finally, we compared 2238 patients with ischemic heart disease with 4474 control subjects and 612 patients with ischemic cerebrovascular disease with 1224 control subjects. We measured levels of high-sensitivity CRP and conducted genotyping for four CRP polymorphisms and two apolipoprotein E polymorphisms. RESULTS: The risk of ischemic heart disease and ischemic cerebrovascular disease was increased by a factor of 1.6 and 1.3, respectively, in persons who had CRP levels above 3 mg per liter, as compared with persons who had CRP levels below 1 mg per liter. Genotype combinations of the four CRP polymorphisms were associated with an increase in CRP levels of up to 64%, resulting in a theoretically predicted increased risk of up to 32% for ischemic heart disease and up to 25% for ischemic cerebrovascular disease. However, these genotype combinations were not associated with an increased risk of ischemic vascular disease. In contrast, apolipoprotein E genotypes were associated with both elevated cholesterol levels and an increased risk of ischemic heart disease. CONCLUSIONS: Polymorphisms in the CRP gene are associated with marked increases in CRP levels and thus with a theoretically predicted increase in the risk of ischemic vascular disease. However, these polymorphisms are not in themselves associated with an increased risk of ischemic vascular disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additional biomarkers, including apo B, lipoprotein(a), high-sensitivity C-reactive protein (CRP), coronary artery calcification score, and ankle-brachial index, are independent risk factors associated with increased risk of ASCVD events and may be helpful when the lipid management goal is unclear.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [284]
In the citing paper
“The value of hsCRP as a CV risk factor appears similar to that of conventional CV risk factors – hsCRP is not a causal factor for CV disease and serves as a biomarker only [36].”
From Impact of semaglutide on high-sensitivity C-reactive protein: exploratory patient-level analyses of SUSTAIN and PIONEER randomized clinical trials (2022) · cites this paper as [36]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death [510,511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
In the citing paper
“Yet, despite the high CV morbidity and mortality risk, PAD patients are usually inadequately managed compared with CAD patients [511].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [511]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Danesh, J., Wheeler, J. G., Hirschfield, G. M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G. D. O., Pepys, M. B., & Gudnason, V. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032804 · Cited by 2,953
Clinical application of C-reactive protein for cardiovascular disease detection and prevention
Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000053730.47739.3c · Cited by 2,513
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Self-citationFasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
Newly identified loci that influence lipid concentrations and risk of coronary artery disease
Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Mendelian randomization: prospects, potentials, and limitations
Smith, G. D. (2004) · International Journal of Epidemiology · doi:10.1093/ije/dyh132 · Cited by 1,222
Clarke, R., Shipley, M., Lewington, S., Youngman, L., Collins, R., Marmot, M., & Peto, R. (1999) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a010013 · Cited by 877
Cited by
Items 801–840 of 840
Extracellular Vesicles for risk stratification in coronary artery disease: Trash or Treasure
Dekker, M. (2022) · Utrecht University Repository (Utrecht University) · doi:10.33540/945
Depta, J. P., & Krasuski, R. A. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32832b7154
Polymorphismes de la CRP et maladies vasculaires ischémiques
(2009) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(09)70121-2
Genetic Epidemiology of Atherosclerotic Vascular Disease
O’Donnell, C. J., & Fu, Y. (2014) · Springer eBooks · doi:10.1007/978-3-642-37393-0_47-1
C-reactive protein: a predictive marker, not a causal factor, for cardiovascular disease
(2009) · Nature Reviews Cardiology · doi:10.1038/ncpcardio1425
High levels of C-reactive protein do not increase the risk of ischemic vascular disease
(2009) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1029
Eapen, D. J., Faaborg-Andersen, C. C., DeStefano, R. J., Karagiannis, A. D., Quintana, R. A., Dhindsa, D. S., Chaudhuri, M., Searles, C. D., & Sperling, L. S. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-822546-2.00026-5
Mendelian Randomization to Evaluate the Causal Effect of Serum Bilirubin on Atrial Fibrillation
Hisamatsu, T. (2023) · Korean Circulation Journal · doi:10.4070/kcj.2023.0075
Laboratory Assessment of Lipoproteins in Type 2 Diabetes
SULLIVAN, D. R. (2023) · Contemporary diabetes · doi:10.1007/978-3-031-26681-2_1
C-reactive protein and risk of venous thromboembolism - results from the MEGA study
Yap, E. S., Brækkan, S. K., Lijfering, W. M., Rosendaal, F. R., Cannegieter, S. C., & Scheres, L. J. J. (2026) · Thrombosis Research · doi:10.1016/j.thromres.2026.109668
A Commentary on “Does Black Box AI in Medicine Compromise Informed Consent?”
Golemon, L. (2025) · Philosophy & Technology · doi:10.1007/s13347-025-00997-z
ACUTE EFFECTS OF LONG DISTANCE RUNNING ON C-REACTIVE PROTEIN AND ARTERIAL STIFFNESS
Durocher, B. E. (2014)
Chackathayil, J. (2013) · University of Birmingham Institutional Research Archive (University of Birmingham)
Allin, K. H., Nordestgaard, B. G., Flyger, H., & Bojesen, S. E. (2020) · Figshare · doi:10.6084/m9.figshare.12873923
Self-citationAllin, K. H., Nordestgaard, B. G., Flyger, H., & Bojesen, S. E. (2020) · Figshare · doi:10.6084/m9.figshare.12873929
Self-citationNěmečková, I., Eissazadeh, S., Rathouska, J., Šilhavý, J., Malínská, H., Pravenec, M. (., & Nachtigal, P. (2024) · Figshare · doi:10.6084/m9.figshare.26707397
Mosenzon, O., Capehorn, M. S., Remigis, A. D., Rasmussen, S., Weimers, P., & Rosenstock, J. (2022) · Figshare · doi:10.6084/m9.figshare.20882123
Allin, K. H., Nordestgaard, B. G., Flyger, H., & Bojesen, S. E. (2020) · Figshare · doi:10.6084/m9.figshare.12873920
Self-citationAllin, K. H., Nordestgaard, B. G., Flyger, H., & Bojesen, S. E. (2020) · Figshare · doi:10.6084/m9.figshare.12873926
Self-citationКаминный, А. И., Shuvalova, Y. A., Kaminnaya, V. I., & Палеев, Ф. Н. (2025) · Russian Cardiology Bulletin · doi:10.17116/cardiobulletin2025200415 · Cited by 1
Geng, Z., Qi, K., Yu, L., Ruan, Y., Gu, J., & Song, S. (2026) · Glycoconjugate Journal · doi:10.1007/s10719-025-10207-9
Zhang, Z., Zhao, L. Y., Wang, Z., Zhou, X., Li, X. X., Yang, W., & Xu, M. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70491 · Cited by 1
Vascular Effects of Inflammation and Oxidative Stress in CKD
Chmielewski, M. S., Lindholm, B., & Stenvinkel, P. (2014) · Springer eBooks · doi:10.1007/978-3-319-09162-4_6
“strated that even marked elevations in CRP concentrations do not increase the risk of cardiovascular disease (CVD) [ 34 , 35 ].”
BackgroundOualla‐Bachiri, W., Lago-Sampedro, A. M., García‐Escobar, E., Maldonado‐Araque, C., Delgado, E., Chaves, F. J., Castaño, L., Calle‐Pascual, A. L., Franch‐Nadal, J., Olveira, G., et al. (2026) · European Journal of Clinical Investigation · doi:10.1111/eci.70179
Kyhl, L. K., Nordestgaard, B. G., Tybjærg‐Hansen, A., Pham, M. H. C., Kühl, J. T., Kofoed, K. F., & Nielsen, S. P. (2026) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2026.106834
Self-citationDifferent CRP Cutoff Values in East Asian Patients
Abbate, A., Garshick, M. S., & Weber, B. (2026) · JACC Asia · doi:10.1016/j.jacasi.2026.02.010
Jang, H., & Seo, H. (2026) · Korean Journal of Clinical Laboratory Science · doi:10.15324/kjcls.2026.58.1.63
Cerebrovascular integrity maintenance and inflammation in atherosclerosis animal models
Cataldo, V. D. (2016) · theses.fr (ABES) · doi:10.70675/7b5a6c4bz3377z40fezbf48z5da7afd1a502
Noroozi, H., Ghaderi, A., & Gholami, M. (2026) · Gene Reports · doi:10.1016/j.genrep.2026.102509
Genetics and Genomics of Coronary Artery Disease: What We Have Learned
McPherson, R. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.01.051 · Cited by 1
young-hye, C., Choi, J. I., & Lee, S. Y. (2026) · World Journal of Diabetes · doi:10.4239/wjd.120422
Nwhator, S. O., Ogunwemimo, M. T., Akinyele, O. A., Adetunji, T. A., Onabanjo, O. A., Ogunleye, B. A., Adewole, K. O., Adewole, O. M., Ojo, I. O., Ogundiran, T., et al. (2026) · American Heart Journal Plus Cardiology Research and Practice · doi:10.1016/j.ahjo.2026.100808
CRP (C-Reactive Protein) Revisited: An Old Yet New Biomarker of Acute and Chronic Inflammation
Nagasawa, M. (2026) · Cells · doi:10.3390/cells15110998 · Cited by 2
“…been developed to measure changes in CRP levels as low as approximately 0.01 mg/dL, and in recent years, attention has been drawn to the fact that these measurements (hs-CRP) are useful as biomarkers reflecting the risk of long-term cardiovascular complications and diabetic complications [52–55].”
InfluentialGene–environment interactions shape cytokine-mediated inflammation and cardiovascular risk
Corianò, M., Tahasildar, S., Huang, L., Rjoob, K. W. Y., Vafaeezadeh, M., Kalaie, S., Jin, Z., Curran, L., Gifani, P., Dumas, M., et al. (2026) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwag435
Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes
Patel, K. V., Chiu, L., Garcia, K. R., Belalcazar, L. M., Segar, M. W., Butler, J., Espeland, M., Ballantyne, C. M., & Pandey, A. (2026) · JACC Heart Failure · doi:10.1016/j.jchf.2026.103296 · Cited by 1
Infiammazione cronica e rischio cardiovascolare nell'uremia: analisi dello studio RISCAVID
PIZZELLA, F. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Prota, D. C. G. (2026) · Evidencia actualizacion en la práctica ambulatoria · doi:10.51987/evidencia.v29i4.7236
Oxidants and antioxidants in cardiovascular disease
Ekblom, K. (2010) · DiVA at Umeå University (Umeå University)
Pentraxins and Atherosclerosis
Barbati, E., Bottazzi, B., Catapano, A. L., Garlanda, C., Latini, R., Mantovani, A., Norata, G. D., & Valentino, S. (2011) · Springer eBooks · doi:10.1007/978-3-7091-0338-8_11
Metadata
- Authors
- Zacho, J., Tybjærg-Hansen, A., Jensen, J. S., Grande, P., Sillesen, H., & Nordestgaard, B. G.
- Affiliations
- University of Copenhagen (DK)
- Herlev Hospital (DK)
- Rigshospitalet (DK)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2008-10-30
- Volume
- 359
- Issue
- 18
- Pages
- 1897-1908
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2081615427
- Cited by
- 839
- References
- 36
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 21 · 2023: 21 · 2022: 26 · 2021: 25 · 2020: 33 · 2019: 25 · 2018: 28 · 2017: 40 · 2016: 48 · 2015: 44 · 2014: 61 · 2013: 56 · 2012: 76
- FWCI
- 102.24
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Life Sciences › Immunology and Microbiology › Immunology › Biomarkers in Disease Mechanisms
- Keywords
- C-reactive protein, ischemic heart disease, ischemic cerebrovascular disease, ischemic vascular disease, CRP gene polymorphisms, apolipoprotein E, high-sensitivity CRP, genetic association, cholesterol levels, causal relationship
- MeSH terms
- C-Reactive Protein, Cerebrovascular Disorders, Cross-Sectional Studies, Female, Humans, Male, Polymorphism, Genetic, Risk Factors, Cohort Studies, Biomarkers, Myocardial Ischemia, Genetic Predisposition to Disease, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.